In what is the first in the field of gene therapy, Spark Therapeutics’ Luxturna has been granted Food and Drug Administration (FDA) approval. Shares of the stock quickly soaed almost 7% before retracing and closing down 0.2% on Tuesday. According to FDA Commissioner Scott Gottlieb, the approval marks another first in gene therapy. The approval … Continue reading “The FDA Has Approved Spark Therapeutics’ Luxturna Therapy”